The project objective is to evaluate the efficacy of the neoadjuvant treatment with
bevacizumab, capecitabine and radiotherapy, in patients with rectal adenocarcinoma resectable
locally advanced (stage T3 or T4), with or without presence of ganglionar metastases and
without distant metastases.